Company news

Lantern Pharma Inc. news in 2021

Lantern Pharma Inc.'s news releases, calls and decks from 2021, newest first.

View company

Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting

December 13, 2021

Lantern Pharma Announces Share Repurchase Program

November 21, 2021

Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted for Presentation at the Society for Neuro-Oncology 2021 Annual Meeting

November 10, 2021

Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting

November 3, 2021

Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights

October 31, 2021

Lantern Pharma to Host Third Quarter 2021 Operating & Financial Results Conference Call on Monday, November 1, 2021 at 4: 30 p.m. ET

October 24, 2021

Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer

September 27, 2021

Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

September 1, 2021

FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas

August 29, 2021

Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration

August 18, 2021

Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer

August 15, 2021

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer

August 10, 2021

Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights

July 28, 2021

Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S

July 26, 2021

Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184

July 19, 2021

Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights

May 2, 2021

Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget

April 25, 2021

Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns Hopkins

March 31, 2021

Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021

March 22, 2021

Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties

March 16, 2021

Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights

March 9, 2021

Lantern Pharma to Host Fourth Quarter and Fiscal Year End 2020 Operating and Financial Results Conference Call on March 10, 2021 at 4: 00 p.m. ET

March 2, 2021

Lantern Pharma Announces Closing of Public Offering of $69 Million USD and Full Exercise of Underwriter's Over-Allotment Option

January 19, 2021

Lantern Pharma Announces Pricing of $60 Million Public Offering

January 13, 2021

Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma

January 3, 2021

Calls in 2021

Decks in 2021